265-OR: Understanding Patterns of GLP-1/GLP-1 RA Use among Individuals with Type 1 Diabetes—A T1D Exchange (T1DX) Online Registry Analysis
Authors: MILLER KELLEE , NGUYEN HUYEN , SHERR JENNIFER L. , KUDVA YOGISH C. , CARLSON ANDERS L. , CHAYTOR NAOMI , DESALVO DANIEL , HILLIARD MARISA E. , MARKS BRYNN E. , LITCHMAN MICHELLE L. , BERGET CARI , WOLF WENDY 
Published: June 2024

Introduction and Objective: Several GLP-1 drugs are FDA approved for type 2 diabetes (T2D) or obesity. The 2024 ADA standards of care highlight that for individuals with T2D and obesity/overweight, GLP-1 therapy is preferred. While many adults with T1D are overweight/obese, GLP-1 use in this population is not well characterized. Data from the T1D Exchange Online Registry was leveraged to assess self-reported GLP-1 use by demographic and clinical characteristics.

Methods: Registry participants complete questionnaires annually. This analysis includes T1D adults who completed a questionnaire in 2023.

Results: Among 8,053 adults, 470 (5.8%) reported using a GLP-1, % using GLP-1 by characteristics are shown in the Table. Median HbA1c was similar in those using (6.6%) and not using (6.5%) GLP-1. GLP-1 use was more common in adults with obesity and cardiovascular disease and less common among those with severe hypoglycemia. Among those with known GLP-1 type (n=109), 67% used semaglutide, 16% tirzepatide, 10% dulaglutide, 6% liraglutide and 1% exenatide.

Conclusion: GLP-1 use in this cohort of adults with T1D is low despite increasing prevalence of obesity. With increased focus on treatment of obesity, trends of GLP-1 use in those with T1D may change over time. Considering the benefits of these agents, further prospective research focused on this population is needed.

Disclosure

K. Miller: Consultant; Dexcom, Inc. Research Support; Dexcom, Inc. H. Nguyen: None. J.L. Sherr: Consultant; Medtronic. Advisory Panel; Medtronic, Insulet Corporation. Speaker's Bureau; Insulet Corporation. Advisory Panel; Vertex Pharmaceuticals Incorporated, MannKind Corporation, StartUp Health T1D Moonshot, Bigfoot Biomedical, Inc., Cecelia Health. Speaker's Bureau; Zealand Pharma A/S. Y.C. Kudva: Research Support; Dexcom, Inc. Other Relationship; Tandem Diabetes Care, Inc., Medtronic. A.L. Carlson: Research Support; Medtronic, Insulet Corporation, Tandem Diabetes Care, Inc., Eli Lilly and Company, Sanofi. Other Relationship; Novo Nordisk. Advisory Panel; MannKind Corporation. Research Support; Dexcom, Inc. N. Chaytor: None. D. DeSalvo: Advisory Panel; Insulet Corporation. Consultant; Dexcom, Inc. M.E. Hilliard: None. B.E. Marks: Research Support; Tandem Diabetes Care, Inc., Dexcom, Inc., Medtronic, Digostics. Advisory Panel; International Society for Pediatric and Adolescent Diabetes, American Diabetes Association, T1D Exchange. Board Member; Juvenile Diabetes Research Foundation (JDRF). M.L. Litchman: Research Support; American Diabetes Association, Association of Diabetes Care & Education Specialists, Dexcom, Inc. Other Relationship; Association of Diabetes Care & Education Specialists. Research Support; National Institutes of Health. C. Berget: Speaker's Bureau; Dexcom, Inc., Insulet Corporation, embecta. W. Wolf: None.

Funding

The Leona M. and Harry B. Helmsley Charitable Trust (G-2103-05086)